NURPF
US OTC
Neuren Pharmaceuticals Limited
Overview
NURPF
Symbol
US OTC
Exchange
About stock

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes.

In addition, it provides development services; and holds loan funded shares.

Neuren Pharmaceuticals Limited dividend calculator
Report issue